麻豆传媒

Meeting Coverage >

ASH: Hematology

Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL

Cytokine release syndrome developed in all patients, including grade 3/4 events in nearly half

New Standard for Newly Diagnosed Pediatric B-Cell Acute Lymphoblastic Leukemia

Blinatumomab consolidation reduced risk of relapse by 61% versus chemotherapy alone

Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP

Drug may potentially "transform" approach to upfront treatment, investigator says

Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimetic

Rusfertide maintained hematocrit

Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma

Will results revive ibrutinib role in MCL following withdrawal of accelerated approval?

'Half-Matched' BMTs Effective in Severe Sickle Cell Disease

High survival rates observed in patients not normally suitable for transplant

Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder

24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial

Four Drugs Top Three for Upfront Treatment of Multiple Myeloma

Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned

Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia

Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease

Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B

Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments

Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis

Combos with navitoclax or pelabresib led to more patients achieving reductions

Axatilimab Shows Efficacy in Recurrent/Refractory GVHD

Highest overall response rate and least toxicity seen with lowest dose

MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia

No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD

ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission

Better 2-year PFS, OS, but not applicable to primary refractory disease

Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients

Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear

Emicizumab Safe, Effective, in Infants With Hemophilia A

More than half of children in study had no treated bleeds at follow-up of more than 100 weeks

Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease

Near complete resolution of pain events in patients, including adolescents

Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials

Survival 75% worse compared with outcomes seen in registrational studies

Completely Oral Regimen Effective, Feasible in APL

97% of patients alive and relapse-free at 3 years

Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's

3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab

New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT

Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk

'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL

Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease

C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria

Iptacopan improved hemoglobin without transfusion versus current standard of care

High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma

European trial is "practice-changing as of today," says U.S. expert

Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody

Most complete responses lasted 24 months or longer after limited-duration glofitamab

Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL

Phase III study showed 58% reduction in the risk of death versus chemo alone

Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging

Data from St. Jude cohort show higher rates of neurocognitive impairment

Heparin Fails to Stop Miscarriages in Women With Inherited Thrombophilia

No difference in live birth rates with or without blood thinner

Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod

Glycoprotein receptor inhibitor produces four times as many responses as placebo

Black Patients Less Likely to Get Advanced Treatments for PE

Also less likely for patients on Medicare and Medicaid

AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT

Similar outcomes if patients went directly to transplant or received intensive salvage first

Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma

Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients

Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma

Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone

Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT

"We should eliminate these silly neutropenic diets," expert says

Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia

OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy

Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL

Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease

Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma

Updated analysis confirms advantages of less aggressive approach to low-burden disease

Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease

LentiGlobin also normalized hemoglobin and reduced hemolysis markers

Can Dasatinib Dose Be Halved in Low-Risk CML?

Lower dose associated with improved tolerability, similar responses in propensity score analysis

CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL

Patients, trial design, logistics among possible explanations for lack of EFS benefit

1